166 related articles for article (PubMed ID: 28692180)
1. Loss of SRY-box2 (SOX2) expression and its impact on survival of patients with oesophageal adenocarcinoma.
Ten Kate FJC; van Olphen SH; Bruno MJ; Wijnhoven BPL; van Lanschot JJB; Looijenga LHJ; Fitzgerald RC; Biermann K
Br J Surg; 2017 Sep; 104(10):1327-1337. PubMed ID: 28692180
[TBL] [Abstract][Full Text] [Related]
2. The role of biological markers of epithelial to mesenchymal transition in oesophageal adenocarcinoma, an immunohistochemical study.
Prins MJ; Ruurda JP; Lolkema MP; Sitarz R; Ten Kate FJ; van Hillegersberg R
J Clin Pathol; 2015 Jul; 68(7):529-35. PubMed ID: 25855799
[TBL] [Abstract][Full Text] [Related]
3. Integrative analysis of array-comparative genomic hybridisation and matched gene expression profiling data reveals novel genes with prognostic significance in oesophageal adenocarcinoma.
Goh XY; Rees JR; Paterson AL; Chin SF; Marioni JC; Save V; O'Donovan M; Eijk PP; Alderson D; Ylstra B; Caldas C; Fitzgerald RC
Gut; 2011 Oct; 60(10):1317-26. PubMed ID: 21478220
[TBL] [Abstract][Full Text] [Related]
4. Three-gene immunohistochemical panel adds to clinical staging algorithms to predict prognosis for patients with esophageal adenocarcinoma.
Ong CA; Shapiro J; Nason KS; Davison JM; Liu X; Ross-Innes C; O'Donovan M; Dinjens WN; Biermann K; Shannon N; Worster S; Schulz LK; Luketich JD; Wijnhoven BP; Hardwick RH; Fitzgerald RC
J Clin Oncol; 2013 Apr; 31(12):1576-82. PubMed ID: 23509313
[TBL] [Abstract][Full Text] [Related]
5. Loss of CD44 and SOX2 expression is correlated with a poor prognosis in esophageal adenocarcinoma patients.
Honing J; Pavlov KV; Meijer C; Smit JK; Boersma-van Ek W; Karrenbeld A; Burgerhof JG; Kruyt FA; Plukker JT
Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S657-64. PubMed ID: 24833101
[TBL] [Abstract][Full Text] [Related]
6. Outcome of oesophagectomy for adenocarcinoma of the oesophagus and oesophagogastric junction.
Zhang X; Watson DI; Jamieson GG; Lally C; Bessell JR; Devitt PG
ANZ J Surg; 2005 Jul; 75(7):513-9. PubMed ID: 15972033
[TBL] [Abstract][Full Text] [Related]
7. Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma.
Noble F; Mellows T; McCormick Matthews LH; Bateman AC; Harris S; Underwood TJ; Byrne JP; Bailey IS; Sharland DM; Kelly JJ; Primrose JN; Sahota SS; Bateman AR; Thomas GJ; Ottensmeier CH
Cancer Immunol Immunother; 2016 Jun; 65(6):651-62. PubMed ID: 27020682
[TBL] [Abstract][Full Text] [Related]
8. P53 and SOX2 Protein Expression Predicts Esophageal Adenocarcinoma in Response to Neoadjuvant Chemoradiotherapy.
van Olphen SH; Biermann K; Shapiro J; Wijnhoven BP; Toxopeus EL; van der Gaast A; Stoop HA; van Lanschot JJ; Spaander MC; Bruno MJ; Looijenga LH
Ann Surg; 2017 Feb; 265(2):347-355. PubMed ID: 28059963
[TBL] [Abstract][Full Text] [Related]
9. Population-based cohort study of the management and survival of patients with early-stage oesophageal adenocarcinoma in England.
Chadwick G; Riley S; Hardwick RH; Crosby T; Hoare J; Hanna G; Greenaway K; Varagunam M; Cromwell DA; Groene O
Br J Surg; 2016 Apr; 103(5):544-52. PubMed ID: 26865114
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemoradiotherapy or chemotherapy alone for oesophageal cancer: population-based cohort study.
Kamarajah SK; Phillips AW; Ferri L; Hofstetter WL; Markar SR
Br J Surg; 2021 Apr; 108(4):403-411. PubMed ID: 33755097
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of Sox2 expression in digestive tract cancers: A meta-analysis.
Du XM; Wang LH; Chen XW; Li YX; Li YC; Cao YW
J Huazhong Univ Sci Technolog Med Sci; 2016 Jun; 36(3):305-312. PubMed ID: 27376796
[TBL] [Abstract][Full Text] [Related]
12. Gene expression and immunohistochemical analyses identify SOX2 as major risk factor for overall survival and relapse in Ewing sarcoma patients.
Sannino G; Marchetto A; Ranft A; Jabar S; Zacherl C; Alba-Rubio R; Stein S; Wehweck FS; Kiran MM; Hölting TLB; Musa J; Romero-Pérez L; Cidre-Aranaz F; Knott MML; Li J; Jürgens H; Sastre A; Alonso J; Da Silveira W; Hardiman G; Gerke JS; Orth MF; Hartmann W; Kirchner T; Ohmura S; Dirksen U; Grünewald TGP
EBioMedicine; 2019 Sep; 47():156-162. PubMed ID: 31427232
[TBL] [Abstract][Full Text] [Related]
13. Human epidermal growth factor receptor-2 in oesophageal cancers: an observational study.
Al-Momani H; Barnes R; El-Hadi A; Shah R; Lewis WG; Edwards P
World J Gastroenterol; 2012 Nov; 18(44):6447-51; discussion p.6450. PubMed ID: 23197890
[TBL] [Abstract][Full Text] [Related]
14. Neutrophil to lymphocyte ratio as a predictor of response to neoadjuvant chemotherapy and survival in oesophageal adenocarcinoma.
Powell AGMT; Chin C; Coxon AH; Chalishazar A; Christian A; Roberts SA; Lewis WG
BJS Open; 2020 Jun; 4(3):416-423. PubMed ID: 32232963
[TBL] [Abstract][Full Text] [Related]
15. SOX2-silenced squamous cell carcinoma: a highly malignant form of esophageal cancer with SOX2 promoter hypermethylation.
Maehara R; Fujikura K; Takeuchi K; Akita M; Abe-Suzuki S; Karbanová J; Corbeil D; Itoh T; Kakeji Y; Zen Y
Mod Pathol; 2018 Jan; 31(1):83-92. PubMed ID: 28862264
[TBL] [Abstract][Full Text] [Related]
16. Sox2 protein expression is an independent poor prognostic indicator in stage I lung adenocarcinoma.
Sholl LM; Barletta JA; Yeap BY; Chirieac LR; Hornick JL
Am J Surg Pathol; 2010 Aug; 34(8):1193-8. PubMed ID: 20631605
[TBL] [Abstract][Full Text] [Related]
17. SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer.
Wilbertz T; Wagner P; Petersen K; Stiedl AC; Scheble VJ; Maier S; Reischl M; Mikut R; Altorki NK; Moch H; Fend F; Staebler A; Bass AJ; Meyerson M; Rubin MA; Soltermann A; Lengerke C; Perner S
Mod Pathol; 2011 Jul; 24(7):944-53. PubMed ID: 21460799
[TBL] [Abstract][Full Text] [Related]
18. Cyclooxygenase isoenzyme-2 and vascular endothelial growth factor are associated with poor prognosis in esophageal adenocarcinoma.
Prins MJ; Verhage RJ; ten Kate FJ; van Hillegersberg R
J Gastrointest Surg; 2012 May; 16(5):956-66. PubMed ID: 22258871
[TBL] [Abstract][Full Text] [Related]
19. DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial.
Sundar R; Ng A; Zouridis H; Padmanabhan N; Sheng T; Zhang S; Lee MH; Ooi WF; Qamra A; Inam I; Hewitt LC; So JB; Koh V; Nankivell MG; Langley RE; Allum WH; Cunningham D; Rozen SG; Yong WP; Grabsch HI; Tan P
Eur J Cancer; 2019 Dec; 123():48-57. PubMed ID: 31655359
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical molecular phenotypes of gastric cancer based on SOX2 and CDX2 predict patient outcome.
Camilo V; Barros R; Celestino R; Castro P; Vieira J; Teixeira MR; Carneiro F; Pinto-de-Sousa J; David L; Almeida R
BMC Cancer; 2014 Oct; 14():753. PubMed ID: 25300947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
